News & Articles

The Top 11 Contract Research Organizations (CROs) Shaping the Future of Pharma, Biotech, and Medtech in 2023

Top 11 Contract Research Organizations 2023 | Vision LifeSciences

The Contract Research Organization (CRO) industry is a linchpin in the pharmaceutical, biotech, and medtech sectors. As the global CRO market is expected to skyrocket to $108 billion by 2028, understanding the key players in this space is crucial. This article offers a comprehensive look at the top 11 Contract Research Organizations (CROs) to watch in 2023, comparing them based on market position, revenue, key acquisitions, and innovative offerings.

Labcorp / Fortrea

Labcorp has been a dominant force in the healthcare diagnostics sector and has made significant strides in drug development solutions. In 2015, the company made a game-changing move by acquiring Covance for $6 billion, solidifying its market position.

  • Market Position: Leading provider of comprehensive drug development solutions.
  • Revenue: Not publicly disclosed.
  • Key Acquisitions: Acquired Covance for $6 billion in 2015, along with several other companies like LipoScience and Sequenom.
  • Innovative Offerings: In 2022, Labcorp spun off its CRO segment into a new entity, Fortrea, focusing on clinical trial management and commercialization services.

IQVIA

IQVIA is a global giant in the CRO industry, offering a unique blend of services that combine data science, technology, and human expertise. With a revenue of $14.41 billion in 2022, it stands as the largest CRO in the world.

  • Market Position: World’s largest CRO.
  • Revenue: $14.41 billion in 2022.
  • Key Acquisitions: None disclosed.
  • Innovative Offerings: Offers end-to-end clinical and commercial services, integrating data science, technology, and human expertise.

Parexel

Parexel is a global leader in the CRO industry, offering a wide range of clinical development services. The company was acquired by EQT Private Equity and Goldman Sachs for $8.5 billion in 2021, adding significant financial backing to its operations.

  • Market Position: One of the world’s largest Contract Research Organizations (CROs).
  • Revenue: Not publicly disclosed.
  • Key Acquisitions: Acquired by EQT Private Equity and Goldman Sachs for $8.5 billion in 2021.
  • Innovative Offerings: Provides a full range of Phase I to IV clinical development services with a patient-first approach.

ICON

ICON is a global CRO that specializes in consulting, clinical development, and commercialization services. With a revenue of $7.7 billion in 2022, the company has shown significant growth, particularly in the oncology research sector.

  • Market Position: Top-tier CRO with a global presence.
  • Revenue: $7.7 billion in 2022.
  • Key Acquisitions: None disclosed.
  • Innovative Offerings: Partnerships with Genomics England and IBM Watson have expanded its capabilities in genomic science and oncology research.

PPD

PPD is a leading global CRO known for its premium services and expertise in real-world research. The company solidified its position as a leader in real-world evidence by acquiring Evidera in 2016.

  • Market Position: Leading global CRO.
  • Revenue: Not publicly disclosed.
  • Key Acquisitions: Acquired Evidera in 2016.
  • Innovative Offerings: Known for its expertise in real-world research and evidence.

CTI

CTI Clinical Trial and Consulting Services is a medium-sized global CRO that has driven over 150 new drug and medical device approvals since its inception in 1999. The company acquired Dynakin in 2021 to strengthen its global full-service offerings.

  • Market Position: Medium-sized global CRO.
  • Revenue: Not publicly disclosed.
  • Key Acquisitions: Acquired Dynakin in 2021.
  • Innovative Offerings: Has facilitated over 150 new drug and medical device approvals since its inception in 1999.

PSI

PSI is a fast-growing CRO that specializes in oncology, hematology, infectious diseases, and multiple sclerosis. The company has received CRO Leadership Awards in all core categories for four consecutive years, making it a company to watch.

  • Market Position: Fast-growing CRO.
  • Revenue: Not publicly disclosed.
  • Key Acquisitions: None disclosed.
  • Innovative Offerings: Specializes in fields like oncology, hematology, infectious diseases, and multiple sclerosis.

Medpace

Medpace is a mid-sized CRO that focuses on global clinical research for drugs and devices. Unlike many of its competitors, Medpace has chosen to grow organically, reinvesting in its workforce and maintaining a cohesive office culture.

  • Market Position: Mid-sized CRO focusing on global clinical research.
  • Revenue: Not publicly disclosed, but reported a 27.8% increase in 2022.
  • Key Acquisitions: None disclosed.
  • Innovative Offerings: Chose to grow organically, reinvesting in its workforce.

Vision Lifesciences

Vision Lifesciences emerges as a reliable partner in the challenging landscape of healthcare and clinical trials. The company offers comprehensive services tailored to meet specific goals, leveraging cutting-edge technology and deep industry expertise.

  • Market Position: Reliable partner in healthcare and clinical trials.
  • Revenue: Not publicly disclosed.
  • Key Acquisitions: None disclosed.
  • Innovative Offerings: Offers comprehensive services tailored to meet specific goals, leveraging cutting-edge technology and industry expertise.

Syneos Health

Syneos Health specializes in late-stage clinical trials and has a global reach with operations in over 90 locations. The company generated $5.393 billion in revenue in 2022 and has recently announced AI-driven partnerships to enhance clinical trial efficiency.

  • Market Position: Specializes in late-stage clinical trials.
  • Revenue: $5.393 billion in 2022.
  • Key Acquisitions: None disclosed.
  • Innovative Offerings: Utilizes AI to identify and match clinical trial opportunities more efficiently.

Ergomed

Ergomed offers specialized services to the pharmaceutical industry, particularly in high-growth market segments like oncology and rare diseases. Since its IPO in 2014, the company has completed nine acquisitions, expanding its global footprint.

  • Market Position: Provides specialized services in pharma.
  • Revenue: Not publicly disclosed.
  • Key Acquisitions: Completed nine since its IPO in 2014.
  • Innovative Offerings: Focuses on high-growth market segments like oncology, rare diseases, and pharmacovigilance.

Conclusion

The top 11 Contract Research Organizations (CROs) to watch in 2023 are revolutionizing the pharmaceutical, biotech, and medtech industries. Through strategic collaborations, innovative services, and a commitment to patient-centric approaches, these companies are shaping the future of clinical research and medical science.

Share It

Further Reading